

DAFTAR PUSTAKA

- Agaba, D. C., Migisha, R., Namayanja, R., Katamba, G., Lugobe, H. M., Aheisibwe, H., Twesigomwe, G., & Ashaba, S. (2019). Prevalence and Associated Factors of Metabolic Syndrome among Patients with Severe Mental Illness Attending a Tertiary Hospital in Southwest Uganda. *BioMed Research International*, 2019, 1–8. <https://doi.org/10.1155/2019/1096201>
- Agung, W., & Arulita, I. F. (2016). Faktor Risiko Terjadinya Skizofrenia. *Public Health Perspektive Journal* 1(1).
- Akhfiya, M., & Syamsianah, A. (2018). Kadar Kolesterol Total Wanita Menopause Hiperkolesterolemia Sesudah Pemberian Teh Buah Tin. 5.
- Andari, S. (2017). Pelayanan Sosial Panti Berbasis Agama dalam Merehabilitasi Penderita Skizofrenia, 16(2), 195–208.
- Aryani, F., & Sari, O. (2016). Gambaran Pola Penggunaan Antipsikotik Pada Pasien Skizofrenia Di Ruang Rawat Inap Rumah Sakit Jiwa. 6, 6.
- Aulia, Ellizabet Lisa. (2009). *Stop Merokok*. Yogyakarta: Gerai Ilmu.
- Ayuandira, A. (2012). Hubungan Pola Konsumsi Makan, Status Gizi, Stres Kerja dan Faktor lain dengan Hiperkolesterolemia pada Karyawan PT Semen Padang Tahun 2012. Skripsi. Universitas Indonesia.
- Bruijnzeel, D., Suryadevara, U., & Tandon, R. (2014). Antipsychotic Treatment of Schizophrenia: An update. *Asian Journal of Psychiatry*, 1–5. <https://doi.org/10.1016/j.ajp.2014.08.002>
- Carpenter, W. T., & Buchanan, R. W. (1994). Schizophrenia. *New England Journal of Medicine*, 330(10), 681–690. <https://doi.org/10.1056/NEJM199403103301006>
- Casey, D. E. (2004). Dyslipidemia and Atypical Antipsychotic Drugs. *The Journal of Clinical Psychiatry*, 65(suppl 18), 5244.
- Chang, H.-Y., Yeh, W.-T., Chang, Y.-H., Tsai, K.-S., & Pan, W.-H. (2002). Prevalence of Dyslipidemia and Mean Blood Lipid Values in Taiwan: Results from the Nutrition and Health Survey in Taiwan.
- Chisholm-Burns, M. A. (Ed.). (2016). *Pharmacotherapy principles & practice (Fourth edition)*. McGraw-Hill Education.
- Cho, S. M. J., Lee, H. J., Shim, J. S., Song, B. M., & Kim, H. C. (2020). Associations between age and dyslipidemia are differed by education level: The Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) cohort. *Lipids in Health and Disease*, 19(1), 12. <https://doi.org/10.1186/s12944-020-1189-y>
- Correll, C. U., Frederickson, A. M., Kane, J. M., & Manu, P. (2007). Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

- Schizophrenia Research*, 89(1), 91–100.
<https://doi.org/10.1016/j.schres.2006.08.017>
- Dania, H., Faridah, I. N., Rahmah, K. F., Abdulah, R., Barliana, M. I., & Perwitasari, D. A. (2019). Hubungan Pemberian Terapi Antipsikotik terhadap Kejadian Efek Samping Sindrom Ekstrapiramidal pada Pasien Rawat Jalan di Salah Satu Rumah Sakit di Bantul, Yogyakarta. *Indonesian Journal of Clinical Pharmacy*, 8(1).
<https://doi.org/10.15416/ijcp.2019.8.1.19>
- Darsana, I. W., & Suariyani, N. L. P. (2020). Trend Karakteristik Pasien Skizofrenia di Rumah Sakit Rawat Jiwa Provinsi Bali (2013-2018). *Archive of Community Health*, 7(1), 41–51.
<https://doi.org/10.24843/ACH.2020.v07.i01.p05>
- Delacr  taz, A., Vandenberghe, F., Gholam-Rezaee, M., Saigi Morgui, N., Glatard, A., Thonney, J., Solida-Tozzi, A., Kolly, S., Gallo, S. F., Baumann, P., Berney, S., Zulauff, S. V., Aubry, J.-M., Hasler, R., Ebbing, K., von Gunten, A., Conus, P., & Eap, C. B. (2018). Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia. *Journal of Clinical Lipidology*, 12(1), 219–229. <https://doi.org/10.1016/j.jacl.2017.10.002>
- Destiana, D., & Timan, I. S. (2018). The Relationship Between Hypercholesterolemia As A Risk Factor For Stroke And Blood Viscosity Measured Using Digital Microcapillary®. *Journal of Physics: Conference Series*, 1073, 042045. <https://doi.org/10.1088/1742-6596/1073/4/042045>
- Dewi, Shinta, S. (2015). *Hubungan Asupan Serat Dengan Kadar Kolesterol Pada Penderita Penyakit Jantung Koroner Rawat Jalan Di Rsud Dr. Moewardi Surakarta*. Skripsi Sarjana. Fakultas Ilmu Kesehatan. Universitas Muhammadiyah Surakarta, Surakarta.
- DiPiro, J. T. (Ed.). (2020). *Pharmacotherapy: A pathophysiologic approach* (Eleventh edition). McGraw Hill Medical.
- Farizah, N. A., Fitriany, E., & Nugrahayu, E. Y. (2020). Hubungan Fungsi Sosial dengan Kualitas Hidup Pasien Skizofrenia Rawat Jalan di Rumah Sakit Jiwa Daerah Atma Husada Mahakam Samarinda. *Motiva: Jurnal Psikologi*, 2(2), 43–50. <https://doi.org/10.31293/mv.v2i2.4436>
- Febriani, D., & Febriani, B. (2018). The Effect of Lifestyle on Hypercholesterolemia. *The Open Public Health Journal*, 11(1), 526–532. <https://doi.org/10.2174/1874944501811010526>
- Foley, D. L., & Morley, K. I. (2011). Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. *Archives of General*

- Psychiatry*, 68(6), 609–616.
<https://doi.org/10.1001/archgenpsychiatry.2011.2>
- Gunawan, E. C. (2017). *Pengolahan Menu Makanan Bagi Penderita Kolesterol Di RSUD Dr. R. Goeteng Taroenadibrata Purbalingga* [Monograph]. Unika Soegijapranata Semarang. <http://repository.unika.ac.id/14632/>
- Gupta, R., Sharma, M., Goyal, N. K., Bansal, P., Lodha, S., & Sharma, K. K. (2016). Gender Differences In 7 Years Trends In Cholesterol Lipoproteins And Lipids In India: Insights From A Hospital Database. *Indian Journal of Endocrinology and Metabolism*, 20(2), 211–218.
<https://doi.org/10.4103/2230-8210.176362>
- Gogos, A., Sbisa, A. M., Sun, J., Gibbons, A., Udawela, M., & Dean, B. (2015). A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings. *International Journal of Endocrinology*, 2015, 615356.
<https://doi.org/10.1155/2015/615356>
- Gonçalves, P., Araújo, J. R., & Martel, F. (2015). Antipsychotics-induced metabolic alterations: Focus on adipose tissue and molecular mechanisms. *European Neuropsychopharmacology*, 25(1), 1–16.
<https://doi.org/10.1016/j.euroneuro.2014.11.008>
- Grant, S., & Fitton, A. (1994). Risperidone: A Review of its Pharmacology and Therapeutic Potential in the Treatment of Schizophrenia. *Drugs*, 48(2), 253–273. <https://doi.org/10.2165/00003495-199448020-00009>
- Hanief, N., & Noor, N. (2021). Gambaran Penggunaan Obat Antipsikotik Pada Pasien Skizofrenia di Rumah Sakit Jiwa Dr. Soeharto Heerdjan Periode Januari – Juni 2017. *Yarsi Journal of Pharmacology*, 2(1), 13–24.
- Heald, A., Pendlebury, J., Anderson, S., Narayan, V., Guy, M., Gibson, M., Haddad, P., & Livingston, M. (2017). Lifestyle factors and the metabolic syndrome in Schizophrenia: A cross-sectional study. *Annals of General Psychiatry*, 16(1), 12. <https://doi.org/10.1186/s12991-017-0134-6>
- Hunter, R., Kennedy, E., Song, F., Gadon, L., & Irving, C. B. (2003). Risperidone versus typical antipsychotic medication for schizophrenia. *Cochrane Database of Systematic Reviews*, 2.
<https://doi.org/10.1002/14651858.CD000440>
- Ikawati, Z. (2018). *Tata Laksana Terapi Penyakit Sistem Syaraf Pusat (Pertama)*. 249-280. Yogyakarta: Bursa Ilmu.
- Ikawati, Z., & Kristanto, C. S. (2021). *Perbandingan Efektivitas Regimen Terapi Antipsikotik Pasien Schizophrenia di RSJ Dr. Ernaldi Bahar Palembang*, 17(2), 11.
- Jentsch, J. (1999). The Neuropsychopharmacology of Phencyclidine From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia.

- Neuropsychopharmacology*, 20(3), 201–225.
[https://doi.org/10.1016/S0893-133X\(98\)00060-8](https://doi.org/10.1016/S0893-133X(98)00060-8)
- Jim, E. L. (2013). Metabolisme Lipoprotein. *Jurnal Biomedik: JBM*, 5(3), Article 3. <https://doi.org/10.35790/jbm.5.3.2013.4335>
- Kementerian Kesehatan RI. (2015). *Keputusan Menteri Kesehatan RI Nomor HK.02.02/MENKES/73/2015 tentang Pedoman Nasional Pelayanan Kedokteran Jiwa*. Kementerian Kesehatan RI. 24-25.
- Kementerian Kesehatan RI. (2019). *Persebaran Prevalensi Skizofrenia/Psikosis di Indonesia*.
<https://databoks.katadata.co.id/datapublish/2019/10/08/persebaran-prevalensi-skizofreniapsikosis-di-indonesia>. (diakses pada 13 Oktober 2022).
- Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L. S., Kreyenbuhl, J., Revicki, D., & Buchanan, R. W. (2002). An Assessment of the Independent Effects of Olanzapine and Risperidone Exposure on the Risk of Hyperlipidemia in Schizophrenic Patients. *Archives of General Psychiatry*, 59(11), 1021. <https://doi.org/10.1001/archpsyc.59.11.1021>
- Koro, C. E., & Meyer, J. M. (2004). The effects of antipsychotic therapy on serum lipids: A comprehensive review. *Schizophrenia Research*, 70(1), 1–17. <https://doi.org/10.1016/j.schres.2004.01.014>
- Krispila, A., Kahanjak, D. N., & Mutiasari, D. (2022). Literature Review: Pengaruh Konsumsi Kopi Terhadap Kadar Kolesterol Pada Pengkonsumsi Kopi. *Jurnal Kedokteran Universitas Palangka Raya*, 10(2), 36–40. <https://doi.org/10.37304/jkupr.v10i2.5522>
- Lally, J., & MacCabe, J. H. (2015). Antipsychotic medication in schizophrenia: A review. *British Medical Bulletin*, 114(1), 169–179. <https://doi.org/10.1093/bmb/ldv017>
- Laurentia, Y.S. (2012). Dislipidemia pada Obesitas dan Tidak Obesitas di RSUP Dr. Kariadi dan Laboratorium Klinik Swasta di Semarang. *Jurnal Fakultas Kedokteran Universitas Diponogoro*. Hal:3.
- Lavretsky H. (2008). *History of Schizophrenia as a Psychiatric Disorder*. In: Mueser KT, Jeste DV. *Clinical Handbook of Schizophrenia*. 3-12. New York: Guilford Press.
- Leadbetter, R., Shutty, M., Pavalonis, D., Vieweg, V., Higgins, P., & Downs, M. (1992). Clozapine-Induced Weight Gain: Prevalence And Clinical Relevance. *The American Journal of Psychiatry*, 149(1), 68–72. <https://doi.org/10.1176/ajp.149.1.68>
- Lee, J. S., Kwon, J. S., Kim, D., Kim, S.-W., Kim, J.-J., Kim, J.-H., Nam, H. J., Ryu, S., Park, I. H., An, S. K., Oh, H.-S., Won, S., Lee, K., Lee, K. Y., Lee,

- S.-H., Lee, Y. S., Yi, J.-S., Hong, K. S., & Joo, Y. H. (2017). Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study. *Psychiatry Investigation*, 14(1), 44. <https://doi.org/10.4306/pi.2017.14.1.44>
- Lehman, AF., Lieberman, JA., Dixon, LB., 2004. Practice guideline for the treatment of patients with schizophrenia, second edition. *Am. J. Psychiatry* 161: 1–56.
- Lexicomp. (n.d.). Retrieved November 8, 2022, from https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668992?cesid=5ebTA77ckiu&searchUrl=%2Fico%2Faction%2Fsearch%3Fq%3DrisperiDONE%26t%3Dname%26acs%3Dtrue%26acq%3Drisper#
- Lombo, V. R., Purwanto, D. S., & Masinem, T. V. (2012). Gambaran Kadar Kolesterol Total Darah Pada Laki-Laki Usia 40-59 Tahun dengan Indeks Massa Tubuh 18,5-22,9 kg/m². *Jurnal Biomedik: JBM*, 4(3), Article 3. <https://doi.org/10.35790/jbm.4.3.2012.1216>
- Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richter, D. J., Sabatine, M. S., Taskinen, M.-R., ... Patel, R. S. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. *European Heart Journal*, 41(1), 111–188. <https://doi.org/10.1093/eurheartj/ehz455>
- Mamat, & Sudikno. (2010). Faktor-Faktor yang Berhubungan dengan Kadar Kolesterol HDL (Analisis Data of The Indonesian Family Life Survey 2007/2008). *Gizi Indonesia*, 33(2). <https://doi.org/10.36457/gizindo.v33i2.90>
- Maslim, R. (2003). *Diagnosis Gangguan Jiwa, Rujukan Ringkas dari PPDGJ-III*. 48-51. Jakarta: Bagian Ilmu Kedokteran Jiwa Fakultas Kedokteran Unika Atma Jaya.
- McNeil, S. E., Gibbons, J. R., & Cogburn, M. (2022). Risperidone. In StatPearls. *StatPearls Publishing*. <http://www.ncbi.nlm.nih.gov/books/NBK459313/>
- Meyer J. M. (2001). A retrospective comparison of lipid, glucose, and weight changes at one year between olanzapine- and risperidone-treated inpatients [abstract]. *Biol Psychiatry*. 49:536.
- Meyer, J. M. (2002). A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: Metabolic outcomes after 1 year. *The Journal of Clinical Psychiatry*, 63(5), 425–433. <https://doi.org/10.4088/jcp.v63n0509>

- Mueser, K. T., & McGurk, S. R. (2004). Schizophrenia. *The Lancet*, 363(9426), 2063–2072. [https://doi.org/10.1016/S0140-6736\(04\)16458-1](https://doi.org/10.1016/S0140-6736(04)16458-1)
- Mueser, K. T., & Jeste, D. V. (Eds.). (2008). *Clinical handbook of schizophrenia*. New York: Guilford Press.
- Mukaddas, A., Faustin, I., & Fahrul, F. (2014). Rasionalitas Penggunaan Antipsikotik pada Pasien Skizofrenia di Instalasi Rawat Inap Jiwa RSD Madani Provinsi Sulawesi Tengah Periode Januari-April 2014. *Online Journal of Natural Science*, 3(2), 18–29.
- Muliyani, M. M. (2019). Karakteristik Pasien Skizofrenia Rawat Jalan di Poli Jiwa RSUD. DR. H. MOCH. Ansari Saleh Banjarmasin. *Jurnal Kajian Ilmiah Kesehatan dan Teknologi*, 1(2), 21–25. <https://doi.org/10.52674/jkikt.v1i2.17>
- Mulyani, N. S., Al Rahmad, A. H., & Jannah, R. (2018). Faktor Risiko Kadar Kolesterol Darah Pada Pasien Rawat Jalan Penderita Jantung Koroner di RSUD Meuraxa. *Action: Aceh Nutrition Journal*, 3(2), 132. <https://doi.org/10.30867/action.v3i2.113>
- Naafi, A. M., Perwitasari, D. A., & Darmawan, E. (2016). Kepatuhan Minum Obat Pasien Rawat Jalan Skizofrenia di Rumah Sakit Jiwa Prof. dr. Soerojo Magelang. *Kartika Jurnal Ilmiah Farmasi*. 4(2), 7-12.
- Nilawati, S., Krisnatuti, D., Mahendra, B., & Gin, O. (2008). *Care Yourself : Kolesterol*. Jakarta: Penebar Plus+.
- NIMH. (n.d.). *Schizophrenia*. National Institute of Mental Health (NIMH). Retrieved October 13, 2022, from <https://www.nimh.nih.gov/health/topics/schizophrenia>
- Nindriani Y, et al. (2013). *Relationship between Smoking and Sports Habits with Total Cholesterol Levels in Traffic Police*.
- Novitayani, S. (2016). Karakteristik Pasien Skizofrenia dengan Riwayat Rehospitalisasi. *Idea Nursing Journal*, 7(3), 23–29. <https://doi.org/10.52199/inj.v7i3.6442>
- Nurrahmani, Ulfah. (2012). *Stop! Kolesterol Tinggi*. Yogyakarta: Group Relasi Inti Media.
- Oktarini, A. L., & Mukaromah, S. B. (2015). Profil Kebugaran (VO2maks) dan Kadar Kolesterol Darah pada Lansia Merokok dan Tidak Merokok. *Journal of Sport Science and Fitness*, 4(4), Article 4. <https://doi.org/10.15294/jssf.v4i4.10097>
- Ortiz-Orendain, J., Castiello-de Obeso, S., Colunga-Lozano, L. E., Hu, Y., Maayan, N., & Adams, C. E. (2017). Antipsychotic Combinations For Schizophrenia. *The Cochrane Database of Systematic Reviews*, 6, CD009005. <https://doi.org/10.1002/14651858.CD009005.pub2>

- Patel, K. R., Cherian, J., Gohil, K., & Atkinson, D. (2014). Schizophrenia: Overview and Treatment Options. *Pharmacy and Therapeutics*, 39(9), 638–645.
- PERKI (Perhimpunan Dokter Spesialis Kardiovaskules Indonesia). (2017). *Panduan Tata Laksana Dislipidemia 2017*. <https://spesialis1.kardio.fk.unair.ac.id/wp-content/uploads/2021/02/PERKI-DYSLIPIDEMIA-2017.pdf>
- Rantung, A. A., Umboh, A., & Mantik, M. F. J. (2014). Hubungan Hiperkolesterolemia dengan Obesitas Pada Siswa SMP Eben Haezar Manado. *e-CliniC*, 2(2). <https://doi.org/10.35790/ec1.2.2.2014.5031>
- Riduwan dan Akdon. (2010). *Rumus dan Data dalam Analisis Data Statistika*. Bandung: Alfabeta.
- Rognoni, C., Bertolani, A., & Jommi, C. (2021). Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects. *Clinical Drug Investigation*, 41(4), 303–319. <https://doi.org/10.1007/s40261-021-01000-1>
- Rojó, L. E., Gaspar, P. A., Silva, H., Risco, L., Arena, P., Cubillos-Robles, K., & Jara, B. (2015). Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. *Pharmacological Research*, 101, 74–85. <https://doi.org/10.1016/j.phrs.2015.07.022>
- Pramono, D. (2010). Determinan terhadap Timbulnya Skizofrenia pada Pasien Rawat Jalan di Rumah Sakit Jiwa Prof. HB Saanin Padang Sumatera Barat. *Berita Kedokteran Masyarakat*, 26(2), 71 – 80.
- Putri, S. R., dan Dian, I. A. (2015). Obesitas sebagai Faktor Risiko Peningkatan Kadar Triglisierida. *Majority*, 4(9), hal. 78-82.
- Sadock, B. J., & Sadock, V. A. (2007). *Kaplan & Sadock's synopsis of psychiatry: Behavioral sciences/clinical psychiatry, 10th ed* (hlm. xv, 1470). Lippincott Williams & Wilkins Publishers. 1470.
- Sari, H., & Sirna, W. (2015). Faktor Predisposisi Penderita Skizofrenia di Poli Klinik Rumah Sakit Jiwa Aceh. *Idea Nursing Journal VI*, 2.
- Sari, P. (2019). Dinamika Psikologi Penderita Skizofrenia Paranoid Yang Sering Mengalami Relapse. *Psikoislamedia Jurnal Psikologi*, 4.
- Solberg, D. K., Bentsen, H., Refsum, H., & Andreassen, O. A. (2016). Lipid Profiles In Schizophrenia Associated With Clinical Traits: A Five Year Follow-Up Study. *BMC Psychiatry*, 16(1), 299. <https://doi.org/10.1186/s12888-016-1006-3>
- Stahl, S. M., Morrisette, D. A., Citrome, L., Saklad, S. R., Cummings, M. A., Meyer, J. M., O'Day, J. A., Dardashti, L. J., & Warburton, K. D. (2013).

- “Metaguidelines” for the management of patients with schizophrenia. *CNS Spectrums*, 18(3), 150–162. <https://doi.org/10.1017/S109285291300014X>
- Stilo, S. A., & Murray, R. M. (2019). Non-Genetic Factors in Schizophrenia. *Current Psychiatry Reports*, 21(10), 100. <https://doi.org/10.1007/s11920-019-1091-3>
- Sudarmono, Afni N., Andri M., & Rafiudin. (2018). *Faktor Risiko Kejadian Skizofrenia di Rumah Sakit Madani Palu*. Fakultas Kesehatan Masyarakat Universitas Muhammadiyah Palu.
- Tisnadjaja, D. (2006). *Bebas Kolesterol & Demam Berdarah*. Depok: Penebar Swadaya.
- Trivedi, R. S., & Anand, A. K. (2013). Effect of smoking on lipid profile. *Gujarat Journal of Otorhinolaryngology and Head and Neck Surgery*, 10, 13–15.
- Tsuang. (2011). Dampak Pribadi Schizophrenia di Eropa. *British Journal of Psychiatry*, 2(69), pp. 125-132.
- Ujiani, S. (2015). Hubungan Antara Usia dan Jenis Kelamin dengan Kadar Kolesterol Penderita Obesitas RSUD Abdul Moeloek Provinsi Lampung. *Jurnal Kesehatan*, 4(1), 43–48.
- Vallianatou, K. (2020). Antipsychotics. *Medicine*, 48(12), 800–803. <https://doi.org/10.1016/j.mpmed.2020.09.002>
- Vantaggiato, C., Panzeri, E., Citterio, A., Orso, G., & Pozzi, M. (2019). Antipsychotics Promote Metabolic Disorders Disrupting Cellular Lipid Metabolism and Trafficking. *Trends in Endocrinology & Metabolism*, 30(3), 189–210. <https://doi.org/10.1016/j.tem.2019.01.003>
- Vázquez-Bourgon, J., Ortiz-García de la Foz, V., Gómez-Revuelta, M., Mayoral-van Son, J., Juncal-Ruiz, M., Garrido-Torres, N., & Crespo-Facorro, B. (2022). Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis. *International Journal of Neuropsychopharmacology*, 25(10), 795–806. <https://doi.org/10.1093/ijnp/pyac033>
- WHO. (2022). *Schizophrenia*. Retrieved October 13, 2022, from <https://www.who.int/news-room/fact-sheets/detail/schizophrenia>
- Yoeantafara, A., & Martini, S. (2017). Pengaruh Pola Makan Terhadap Kadar Kolesterol Total. *Media Kesehatan Masyarakat Indonesia*, 13(4), 304. <https://doi.org/10.30597/mkmi.v13i4.2132>
- Yulianty, M. D., Cahaya, N., & Srikartika, V. M. (2017). Studi Penggunaan Antipsikotik dan Efek Samping pada Pasien Skizofrenia di Rumah Sakit Jiwa Sambang Lihum Kalimantan Selatan. *Jurnal Sains Farmasi & Klinis*, 3(2), 153. <https://doi.org/10.29208/jsfk.2017.3.2.108>

Zhang, Y., Wang, Q., Reynolds, G. P., Yue, W., Deng, W., Yan, H., Tan, L., Wang, C., Yang, G., Lu, T., Wang, L., Zhang, F., Yang, J., Li, K., Lv, L., Tan, Q., Li, Y., Yu, H., *et al.* (2020). Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial. *The Journal of Clinical Psychiatry*, 81(3), 19m12785. <https://doi.org/10.4088/JCP.19m12785>